M

Merus NV
D

MRUS

47.430
USD
-0.21
(-0.44%)
مغلق
حجم التداول
20,372
الربح لكل سهم
-4
العائد الربحي
-
P/E
-12
حجم السوق
3,247,232,390
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CARA
    -0.02000
    (-0.39%)
    5.05000 USD
    P
    PBYI
    -0.01500
    (-0.51%)
    2.90500 USD
    P
    PRTA
    0.270
    (1.77%)
    15.540 USD
    S
    SCYX
    -0.03000
    (-2.65%)
    1.10000 USD
    T
    TNXP
    -0.53000
    (-5.48%)
    9.15000 USD
    المزيد
الأخبار
المقالات

العنوان: Merus NV

القطاع: Healthcare
الصناعة: Biotechnology
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.